LAB Overview

Standard BioTools Inc. has a portfolio of technologies that help biomedical researchers develop medicines faster. The Company develops, manufactures and sells a diversified range of instrumentation, consumables, and services. The Company's Genomics business includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. Its Biomark X9 system for high-throughput genomics delivers scalability for qPCR applications. Designed for researchers who require robust multiplexing capabilities, the Biomark X9 system enables the simultaneous analysis of thousands of reactions in a single run. By leveraging advanced microfluidics technology, it reduces reagent consumption while increasing throughput, making it a solution for large-scale genomic studies, clinical research, and biomarker discovery. The Biomark X9 system integrates with data analysis tools, accelerating workflows and providing comprehensive insights.

Wall Street analysts forecast LAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LAB is1.35 USD with a low forecast of 1.35 USD and a high forecast of 1.35 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Standard BioTools Inc revenue for the last quarter amounts to 23.80M USD, decreased

Standard BioTools Inc. EPS for the last quarter amounts to 0.05 USD, decreased -155.56

Standard BioTools Inc (LAB) has 385 emplpoyees as of March 31 2026.

Today LAB has the market capitalization of 359.49M USD.